Sign In
Buy CSU
$33.30
+0 (+0%)
At Close: Jul 20, 2022
Constellation Software Inc. Announces Release Date for First Quarter Results
06:15pm, Monday, 14'th Apr 2025
TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its first quarter results on May 12, 2025.
Constellation Software: Head For The Stars With This Stellar Compounder
04:26am, Monday, 07'th Apr 2025
Constellation Software has delivered a 34% annualized return since its 2006 IPO, driven by its strategic acquisition of Vertical Market Software businesses. Founder Mark Leonard's long-term focus and
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase II
Constellation Software: The 'Star' Of The Canadian Software Show
01:51am, Wednesday, 12'th Feb 2025
Constellation Software excels in growth via acquisition in the vertical market software space, demonstrating consistent shareholder value creation over decades. CSU's decentralized operatorship and st
Constellation Software Inc. Announces Release Date for Fourth Quarter Results
04:55pm, Tuesday, 11'th Feb 2025
TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its fourth quarter results on March 7, 2025.
Constellation Software Inc. and Topicus.com Inc. announce execution of Treasury Shares Purchase Agreement
07:52pm, Tuesday, 04'th Feb 2025
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TOI.V) today announced that Topicus' subsidiary, Yukon Niebieski Kapital B.V. ("Yukon"), has ent
Constellation Software Inc. and Topicus.com Inc. announce execution of Treasury Shares Purchase Agreement
07:45pm, Tuesday, 04'th Feb 2025
TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TOI.V) today announced that Topicus' subsidiary, Yukon Niebieski Kapital B.V. ("Yukon"), has ent
Constellation Software Inc. Announces Annual Interest Rate for Series 1 Debentures
05:13pm, Tuesday, 21'st Jan 2025
TORONTO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU, TSX: CSU.DB) (the “Company”) announced today that the interest rate applicable to the unsecured subordinated float
Topicus.com Inc. Reaches Agreement to acquire Cipal Schaubroeck in Belgium
08:03am, Tuesday, 14'th Jan 2025
TORONTO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus' subsidiary Total Specific Solutions (TSS) B.V. (“TSS�
Topicus.com Inc. Reaches Agreement to acquire Cipal Schaubroeck in Belgium
08:02am, Tuesday, 14'th Jan 2025
TORONTO, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus' subsidiary Total Specific Solutions (TSS) B.V. (“TSS�
3 Tech Stocks to Buy Before Dec. 31st
10:04am, Wednesday, 18'th Dec 2024
Any investor who has been in the market for the past two decades has mostly benefited from being overweight technology stocks.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
12:59am, Friday, 15'th Nov 2024
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antih
Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2024 and Declares Quarterly Dividend
05:01pm, Friday, 08'th Nov 2024
TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the third quarter ended September
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
03:14pm, Monday, 04'th Nov 2024
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concer
